Nanoscience Approaches in Treating Urinary Tract Infection with Existing Antibiotic Therapy
Abstract
A serious worldwide health emergency has been brought on by the growth of multidrug-resistant (MDR) microorganisms, which are difficult to treat with traditional antimicrobial drugs. This emphasises how urgently novel therapeutic approaches are needed to combat antimicrobial drug resistance (ABR). To increase the efficacy of treatment for resistant microorganisms, one such tactic, known as nAbts mixes antimicrobial medications with nanoparticles. This work looks at the development of nano-based treatment systems to treat ABR, specifically urinary tract infections brought on by pathogenic microbes. Important results show that nAbts are more effective than conventional antibiotics. For instance, in vitro research showed that silver nanoparticle-based nAbts decreased bacterial growth in ciprofloxacin-resistant Escherichia coli strains by 98%, as opposed to the 30–40% reduction seen with ciprofloxacin alone. The capacity of the nanoparticles to break down bacterial cell walls, boost medication penetration, and enable targeted delivery—thereby circumventing resistance mechanisms—is responsible for this notable increase in antimicrobial activity. With their capacity to break down bacterial cell walls and promote intracellular drug accumulation, nAbts hold enormous promise for defeating resistance and providing a major breakthrough in the management of multidrug-resistant illnesses. The promise of nAbts to offer safer, more focused, and more successful treatment alternatives for…
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.